


An Update on the STI R&D Pipeline and Investments

A focus on gonorrhea

Alison Footman, PhD, MPH
Senior Program Manager, STIs
AVAC
November 14, 2024

Gonorrhoea

- WHO estimates 374 million cases of new sexually transmitted infections (STIs) were acquired in 2020, including trichomoniasis, chlamydia, gonorrhoea, and syphilis
 - More than 82 million gonorrhoea cases
- Gonorrhoea has developed resistance to nearly all antibiotics used for treatment
 - New therapeutics are under development, but gonorrhoea could develop resistance to these new treatments
- When left untreated, these infections can lead to severe sexual and reproductive health consequences
- Vaccines to prevent gonorrhoea are under development and of great interest is the 4CMenB vaccine in preventing infections




Sources: Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 (32).
Global HIV, Hepatitis and STIs Programmes (HHS), WHO, 2024.

Gonorrhoea Diagnostics

- Diagnostics currently exist to detect gonorrhoea
 - Expensive
 - Difficult to implement
 - Long times between testing, results, and treatment can lead to under treatment
- Syndromic management is used in many countries with limited testing availability
 - Affordable
 - Can lead to under and over treatment of infections
 - Overuse of antibiotics
- Highlights the need for affordable, accessible, and rapid diagnostics to detect and treat infections to prevent transmission

12.1.2 SEXUALLY ACTIVE WOMEN



Gonorrhea Diagnostics

- The WHO Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022-2030 provides strategies on ending these infections by 2030 and includes several objectives for testing:
 - Support the development and evaluation of new diagnostics and testing strategies for STIs
 - Screen priority populations for asymptomatic infections
 - Enhance laboratory capacity



Speakers

Cécile Ventola, Senior Technical Officer, Impact Global Health

- Review of investments to support the development of STI diagnostics

Birgitta Gleeson, FIND, Switzerland

- Discuss STI diagnostics and the development of a novel gonorrhea lateral flow assay

Mandisa Mdingi, Foundation for Professional Development, South Africa

- Potential impact of a novel gonorrhea lateral flow assay in South Africa

Thank You!



An initiative of **AVAC**

STIWatch

The go-to resource for the latest on STI testing and vaccine R&D.

Learn more at STIWatch.org



The graphic features a dark blue background with a faint world map. At the bottom, there are several purple icons representing different STIs: a virus, a bacterium, a condom, a syringe, a hand, and another virus. The text is in white and light blue.

Alison Footman PhD, MPH
alison@avac.org